Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Elias Jabbour, Koji Sasaki, Ghayas C. Issa, Fadi Haddad, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Musa Yilmaz, Courtney D. DiNardo, Jeffrey Skinner, Naveen Pemmaraju, Sara E Dellasala, Sherry A. Pierce, Jorge E. Cortes, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 809–811.

https://doi.org/10.1182/blood-2022-169772

Published: 2022

Journal Articles

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Kunhwa Kim, Jeffrey Skinner, Sara E Dellasala, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Musa Yilmaz, Naveen Pemmaraju, Guillermo Garcia-Manero, Sherry A. Pierce, Elias Jabbour, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3897–3899.

https://doi.org/10.1182/blood-2022-168604

Published: 2022

Journal Articles

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia

Alex Bataller, Koji Sasaki, Elias Jabbour, Ghayas C. Issa, Fadi Haddad, Jeffrey Skinner, Sara E Dellasala, Guillermo Garcia-Manero, Sherry A. Pierce, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3895–3896.

https://doi.org/10.1182/blood-2022-164924

Published: 2022

Journal Articles

Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Blood (2021) 138 (Supplement 1): 631.

https://doi.org/10.1182/blood-2021-152614

Published: 2021

Journal Articles

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Ghayas C. Issa, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Jeffrey Skinner, MHA, Rita Khouri, Naveen Pemmaraju, MD, Patrice Nasnas, MD, Sara E Dellasala, BS, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-143023

Published: 2020

Journal Articles

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-140003

Published: 2020

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Preetesh Jain, MDDM, PhD, Elias Jabbour, MD, William Wierda, MD PhD, Naveen Pemmaraju, MD, Alessandra Ferrajoli, MD, Sara E Dellasala, RN, Sherry Pierce, BSN, BA, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 1802.

https://doi.org/10.1182/blood.V124.21.1802.1802

Published: 2014

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Maro Ohanian, DO, Mark Levis, MD, PhD, Stefan H. Faderl, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Naval G. Daver, MD, Sara E Dellasala, RN, Sherry Pierce, Jan A. Burger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2013) 122 (21): 3934.

https://doi.org/10.1182/blood.V122.21.3934.3934

Published: 2013

Journal Articles

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Farhad Ravandi, MD, Mona Lisa Alattar, MD, Mark J. Levis, MD, PhD, Guillermo Garcia-Manero, MD, Mary A Richie, RN, Naval G. Daver, MD, Stefan Faderl, MD, Michael Andreeff, MD, PhD, Gautam Borthakur, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Michael R. Grunwald, MD, Sara E Dellasala, RN, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 1519.

https://doi.org/10.1182/blood.V120.21.1519.1519

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

Journal Articles

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Farhad Ravandi, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Charles Asa Koller, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Elizabeth M Burton, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 3617.

https://doi.org/10.1182/blood.V120.21.3617.3617

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

NARROW

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia

Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only